Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study.

Among subjects with complete data at all visits, the mean MSFC score steadily increased during the prospective observation period on treatment with IM IFNb-1a from 0.06 ± 1.64 at baseline to 0.21 ± 1.54 at Visit 5 (12 months, Figure 5 ), indicating a positive trend.

also in 11,005 other papers

In accordance with the AXIOM trial, the majority of trials with IM IFNb-1a showed a trend towards better quality of life, particularly in the physical domains, or at least a stable quality of life [ 19 , 20 , 21 ].

also in 53,322 other papers